Publications scientifiques

Long-term evolution of neuroendocrine cell hyperplasia of infancy: the FRENCHI findings.

Auteurs : Dervaux M, Thumerelle C, Fabre C, Abou-Taam R, Bihouee T, Brouard J, Clement A, Delacourt C, Delestrain C, Epaud R, Ghdifan S, Hadchouel A, Houdouin V, Labouret G, Perisson C, Reix P, Renoux MC, Troussier F, Weiss L, Mazenq J, Nathan N, Dubus JC.

Sources : Eur J Pediatr. 2023 Feb;182(2):949-956.

Inherited pulmonary surfactant metabolism disorders in Argentina: Differences between patients with SFTPC and ABCA3 variants.

Auteurs : Balinotti JE, Mallie C, Maffey A, Colom A, Epaud R, de Becdelievre A, Fanen P, Delestrain C, Medín M, Teper A.

Sources : Pediatr Pulmonol. 2023 Feb;58(2):540-549.

HSPB5 Inhibition by NCI-41356 Reduces Experimental Lung Fibrosis by Blocking TGF-β1 Signaling.

Auteurs : Tanguy J, Boutanquoi PM, Burgy O, Dondaine L, Beltramo G, Uyanik B, Garrido C, Bonniaud P, Bellaye PS, Goirand F.

Sources : Pharmaceuticals (Basel). 2023 Jan 24;16(2):177.

Tolerability, safety and survival in patients with severe pulmonary arterial hypertension treated with intravenous epoprostenol (Veletri®): a prospective, 6-months, open label, observational, non-interventional study.

Auteurs : Degering J, Egenlauf B, Harutyunova S, Benjamin N, Salkić A, Xanthouli P, Eichstaedt CA, Seeger R, Sitbon O, Grünig E.

Sources : Respir Res. 2023 Jan 18;24(1):18.

Deciphering an isolated lung phenotype of NKX2-1 frameshift pathogenic variant.

Auteurs : Delestrain C, Aissat A, Nattes E, Gibertini I, Lacroze V, Simon S, Decrouy X, de Becdelièvre A, Fanen P, Epaud R.

Sources : Front Pediatr. 2023 Jan 17;10:978598.

Involvement of SUR2/Kir6.1 channel in the physiopathology of pulmonary arterial hypertension.

Auteurs : Le Ribeuz H, Masson B, Dutheil M, Boët A, Beauvais A, Sabourin J, De Montpreville VT, Capuano V, Mercier O, Humbert M, Montani D, Antigny F.

Sources : Front Cardiovasc Med. 2023 Jan 10;9:1066047.

Clinical features and outcomes of patients with myositis associated-interstitial lung disease.

Auteurs : Karampitsakos T, Tzilas V, Papaioannou O, Chrysikos S, Vasarmidi E, Juge PA, Vizirianaki S, Bibaki E, Reppa A, Sidiropoulos P, Katsaras M, Sotiropoulou V, Tsiri P, Koulousousa E, Theochari E, Tsirikos G, Christopoulos I, Malakounidou E, Zarkadi E, Sampsonas F, Hillas G, Karageorgas T, Daoussis D, Kalogeropoulou C, Dimakou K, Tzanakis N, Borie R, Dieudé P, Antoniou K, Crestani B, Bouros D, Tzouvelekis A.

Sources : Front Med (Lausanne). 2023 Jan 9;9:1096203.

Sotatercept for the treatment of pulmonary arterial hypertension: PULSAR open-label extension

Auteurs : Humbert M, McLaughlin V, Gibbs JSR, Gomberg-Maitland M, Hoeper MM, Preston IR, Souza R, Waxman AB, Ghofrani HA, Escribano Subias P, Feldman J, Meyer G, Montani D, Olsson KM, Manimaran S, de Oliveira Pena J, Badesch DB.

Sources : Eur Respir J. 2023 Jan 6;61(1):2201347.

Sotatercept for the treatment of pulmonary arterial hypertension: PULSAR open-label extension.

Auteurs : Humbert M, McLaughlin V, Gibbs JSR, Gomberg-Maitland M, Hoeper MM, Preston IR, Souza R, Waxman AB, Ghofrani HA, Escribano Subias P, Feldman J, Meyer G, Montani D, Olsson KM, Manimaran S, de Oliveira Pena J, Badesch DB.

Sources : Eur Respir J. 2023 Jan 6;61(1):2201347.

[Lung transplantation for cystic fibrosis and bronchiectasis].

Auteurs : Renaud-Picard B, Tissot A, Burgel PR, Grenet D, de Miranda S, Coiffard B.

Sources : Rev Mal Respir. 2023 Jan 6:S0761-8425(22)00468-5.